Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice

References

• Fuchs HA, Kaye JJ, Callahan LE, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16(5):585–91.
   PubMed Web of Science ®Google Scholar
• Stenger AA, Van Leeuwen MA, Houtman PM, Bruyn GA, Speerstra F, Barenden BC, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. British J Rheumatol. 1998;37(11):1157–63.
   PubMedGoogle Scholar
• Quinn MA, Conaghan GC, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is evidence? Rheumatology. 2001;40(11):1211–20.
   PubMed Web of Science ®Google Scholar
• van Aken J, Lard LR, le Cessie S, Hazes JM, Beedvelt FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent rheumatoid arthritis. Ann Rheum Dis. 2004;63(3):274–9.
   PubMed Web of Science ®Google Scholar
• Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43(7):906–14.
   PubMed Web of Science ®Google Scholar
• Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R, Ferraccioli G. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis. 2012;72(6):858–62.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative Initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice. Application of American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum. 2011;63(11):3204–15.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, Breedvelt FC, Boumpas D, Bumester G, et al. Treating rheumatoid arthritis to target: recommendations of international task force. Ann Rheum Dis. 2010; 69(4):631–7.
   PubMed Web of Science ®Google Scholar
• Scholes M, Knevel R, Aletaha D, Bijsma JW, Breedvelt FC, Boumpas DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systemic literature search. Ann Rheum Dis. 2010;69(4):638–43.
   PubMed Web of Science ®Google Scholar
• Maini RN, Feldman M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4(Suppl 2):S22–8.
   PubMedGoogle Scholar
• St. Clair EW, Van Der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicentre, randomised, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde DM, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063–74.
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curis JR, et al. American college of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Vaila C, et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75.
   PubMed Web of Science ®Google Scholar
• Singh JR, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–39.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63(12): 3702–11.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified diseases activity scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
   PubMed Web of Science ®Google Scholar
• Mӓkinen H, Hannonen P, Sokka T. Definition of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S22–8.
   Web of Science ®Google Scholar
• Mäkinen H, Kautiainen H, Hannonen P, Möttönen T, Leirisalo-Repo M, Laasonen L, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol. 2007; 34(2):316–21.
   Web of Science ®Google Scholar
• Dougados M, Emery P, Lemmel EM, de la Serna R, Zerbini CA, Brin S, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol. 2003;30(12):2572–9.
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–9.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15(15):323–8.
   PubMedGoogle Scholar
• O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Eng J Med. 1996;334(20):1287–91.
   PubMed Web of Science ®Google Scholar
• Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2009;68(7):1105–12.
   PubMed Web of Science ®Google Scholar
• Tugwel P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate Cyclosporine Combination Study Group. N Engl J Med. 1995;333(3):137–41.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomised double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(9):726–33.
   PubMed Web of Science ®Google Scholar
• Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis. Arthritis Rheum. 2001;44(8):1736–43.
   PubMed Web of Science ®Google Scholar
• Courvoisier N, Dougados M, Chantagrel A, Goupille P, Meyer O, Sibillia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10(5):R106.
   PubMed Web of Science ®Google Scholar
• Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L377 (methotrexate capsule) for the treatment of rheumatoid arthritis (in Japanese). Jpn J Inflamm. 1996;16(6):437–58.
   Google Scholar
• Katayama K, Matsuno T. Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. Mod Rheumatol. 2009;19(5):513–21.
   PubMed Web of Science ®Google Scholar
• Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis. Meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010;62(10):2852–63.
   Web of Science ®Google Scholar
• Dirven L, van der Broek M, Klarenbeek NB, van Krugten MV, van der Lubbe PAHM, Kerstens PJSM, Huizinga, TWJ. Seven year results of DAS steered treatment in the BeSt study: clinical and radiological outcomes. ACR/ARHP Annual Scientific Meeting (Atlanta). 2010; Presentation No.334.
   Google Scholar
• Rantalaiho V, Korpela M, Leasonen L, Kautiainen H, Järvenpää S, Hannonen P, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122.
   PubMed Web of Science ®Google Scholar
• Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64(9):2824–35.
   PubMed Web of Science ®Google Scholar
• Abe C, Kikukawa T, Komatsu Y. Combination therapy on murine arthritis -salazosulfapyridine, bucillamine, and methotrexate. Int J Immunotherapy. 1994;11:129–321.
   Web of Science ®Google Scholar
• Okada M, Matsuno H, Abe C, Katayama K, Kondo M, Sagawa A, et al. Patient-oriented decision of early treatment of rheumatoid arthritis with combination of triple conventional disease modifying anti-rheumatic drugs or tumor necrosis factor inhibitors and methotrexate (prospective, open-label clinical trial). EULAR Annual Scientific Meeting (Madrid). 2013, Presentation No.2232.
   Google Scholar